Raymond James Predicts TSE:MDP FY2029 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Equities researchers at Raymond James issued their FY2029 earnings per share estimates for shares of Medexus Pharmaceuticals in a report released on Tuesday, November 19th. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of $0.89 per share for the year. Raymond James currently has a “Outperform” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other equities research analysts also recently weighed in on MDP. Stifel Nicolaus raised their price target on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, August 12th. Finally, Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of C$5.25.

Medexus Pharmaceuticals Stock Performance

TSE:MDP opened at C$2.15 on Thursday. The firm has a market cap of C$52.74 million, a P/E ratio of 43.00 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.44 and a fifty-two week high of C$3.16. The firm has a 50-day simple moving average of C$2.48 and a two-hundred day simple moving average of C$2.19.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.